ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Moves Forward With Approval From BSA

November 22, 2013

In Brief: Deadline June 1 For Cancer Research Institute Grants; Chabner To Present Karnofsky Lecture

May 3, 1985

Studies Are Demonstrating Effectiveness Of Drug Combinations As Adjuvant Therapy; NCI Will Support New Clinical Trials

April 12, 1974

Researchers Identify Mutation Linked to Inherited Risk of ALL

September 27, 2013

Bristol To Support Grants For Studies On Drug Resistance

June 26, 1987

Review Of Cancer Center supports Grants Needs Refocus On Science, Advisors Say

October 18, 1996